TNF and melanoma: This suggests that combining anti-TNF-α with ICB is a promising strategy for safely managing irEC.341 Moreover, the TICIMEL phase Ib clinical trial (NTC03293784) evaluated the combination of TNF blockers (infliximab or certolizumab) with ICB in 14 advanced melanoma patients (Table 9).342 This trial aimed to assess the safety and antitumor efficacy of these combinations, with a particular focus on managing gastrointestinal side effects.